34 results about "Truncal muscle weakness" patented technology

There remains a need for effective therapeutic agents for the treatment of TGFβ superfamily-associated disorders. [Solution] Polypeptides comprising an activin receptor type IIB (ActRIIB) ectodomain (ECD) variant are provided. In some embodiments, the polypeptides of the present disclosure comprise an ActRIIB-ECD variant fused to an Fc domain portion. The present disclosure also provides pharmaceutical compositions and methods using the polypeptides to treat diseases and conditions associated with TGF-β superfamily ligand signaling, such as metabolic disorders, diabetes, obesity, cardiometabolic disease, pulmonary hypertension, fibrosis, muscle weakness and atrophy, bone damage, and / or low red blood cell levels (e.g., anemia).

The invention relates to application of traditional Chinese medicine herba epimedii, especially an aqueous extract of herba epimedii and epimedin A in prevention and / or improvement of sarcopenia. Compared with a blank control group and a negative control group, the body lengths of the herba epimedii aqueous extract with the concentration of 1 mg / mL, the total flavonoids with the concentration of 0.026 mg / mL, the epimedium A with the concentration of 50 [mu] M, the epimedium B with the concentration of 200 [mu] M, the epimedium C with the concentration of 100 [mu] M, the icariin with the concentration of 200 [mu] M and the icaritin with the concentration of 100 [mu] M are increased by 21.40%, 23.09%, 26.69%, 24.91%, 29.22%, 33.15% and 28.35% respectively. The icariin administration concentration is improved, and the growth promoting effect concentration dependence is obviously enhanced. The body length of the caenorhabditis elegans is increased by 24.19% and even exceeds that of a positive control group. Epimedin A of 50 mu M can effectively increase the body length of caenorhabditis elegans, and other Epimedin A needs higher concentration; 50 [mu] M has the best effect of protecting and relieving the muscular structure. The invention provides a thought for developing medicines for improving dyskinesia and muscle volume reduction, prolonging life, improving muscle fiber atrophy, treating muscle strength decline, tonifying liver and kidney and strengthening muscles and bones, and the medicine is high in safety.

The present invention relates to a method for obtaining a functionally enhanced mitochondria and a use thereof, and specifically, to: a mitochondria isolated from cells overexpressing glutathione synthase; and a use thereof for preventing, alleviating, or treating muscle weakness-related diseases.

This invention discloses a shoulder joint exerciser, including a shoulder brace and an upper arm brace, with a hinged rod assembly between them to maintain deflection. A first rod hinged to the back of the shoulder brace is rotatably connected to the end of a second rod hinged to the back of the upper arm brace. An electric push rod is rotatably mounted on the first rod, with its output end hinged to the second rod and positioned close to the upper arm brace. The device also includes a worm gear, with worm wheels respectively mounted on the shafts connecting the first and second rods to the shoulder brace and upper arm brace, the worm gear meshing with the worm wheels. This shoulder joint exerciser has a simple structure and is easy and quick to operate. It avoids the pain or secondary injury caused by the arm falling rapidly during arm raising and lowering due to muscle weakness or poor coordination.

The present invention relates to a pharmaceutically acceptable acid addition salt comprising: (i) S-indolylcarbamate; and (ii) an organic acid, wherein the organic acid has: a pKa1 greater than or equal to 2.5; and a chemical formula of CxHy(CO2H)z, wherein x is 1 to 10, y is 2 to 20, and z is 1 or 2. The pharmaceutically acceptable acid addition salt is used to treat conditions such as cachexia, sarcopenia, neuromuscular disorders, and muscle weakness.

The application relates to the technical field of intelligent medical auxiliary diagnosis and automatic evaluation of nerve functions, in particular to an NIHSS score automatic evaluation system for stroke patients. The system comprises a multi-modal induction and perception unit, which is used as a front-end data inlet and collects patient responses in real time to generate a video stream containing depth and color information and a synchronous audio stream; a dynamic reference calibration unit, which extracts kinematic characteristics to construct an individualized neural reference template; a neural motion frequency spectrum decomposition unit, which generates a frequency spectrum pathological characteristic vector distinguishing muscle weakness and ataxia; a contralateral mirror inhibition analysis unit, which generates compensation and driving confidence representing real neural driving intentions; a cross-modal reflection analysis unit, which generates a sensory pathway integrity index according to the difference in nerve conduction velocity; and a collaborative scoring decision engine, which maps multi-modal characteristics to a standardized NIHSS score. The application effectively eliminates the interference of age and basic physical fitness on the score, and can also provide high-precision comparison references for subsequent abnormality determination of the affected side.

This invention belongs to the pharmaceutical field and relates to the application of nikkomycin in the preparation of drugs for treating lipid storage myopathy. This invention discloses the use of nikkomycin in the treatment of lipid storage myopathy, particularly in the treatment of simple myopathic neutral lipopathy caused by PNPLA2 gene mutations. Simple myopathic neutral lipopathy is an autosomal recessive, progressive lipid storage myopathy affecting multiple systems throughout the body. Currently, there is no treatment available, and patients develop fatal symptoms such as generalized muscle weakness and cardiomyopathy in the late stages. This invention discovers that nikkomycin can significantly reverse lipid droplet deposition in fibroblasts of patients with simple myopathic neutral lipopathy, reduce inflammatory responses, improve autophagy inhibition, and increase energy production. It can serve as an effective ingredient for treating this disease and has clear application prospects in patients with untreatable simple myopathic neutral lipopathy.

To provide a new male climacteric disorder-ameliorating composition using a safe material free from side effects, and to provide a medicine, food and drink containing the composition.SOLUTION: The male climacteric disorder-improving composition contains a treated product of an Agaricus fruit body.SELECTED DRAWING: Figure 13

There are provided polypeptides that include an Activin receptor type IIB (ActRIIB) ectodomain (ECD) variant. In some embodiments, a polypeptide of the disclosure includes an ActRIIB-ECD variant fused to an Fc domain moiety. The disclosure also provides pharmaceutical compositions and methods of using the polypeptides to treat diseases and conditions associated with TGFβ superfamily ligand signaling, such as metabolic disorders, diabetes, obesity, cardiometabolic disease, pulmonary hypertension, fibrosis, muscle weakness and atrophy, bone damage, and / or low red blood cell levels (such as anemia).

To provide polypeptides and pharmaceutical compositions comprising activin type IIB receptor variants.SOLUTION: The polypeptide of the present invention comprises an extracellular activin type IIB receptor (ActRIIB) mutant comprising an amino acid sequence consisting of a specific sequence, wherein the C-terminus of the ActRIIB mutant is fused to a human IgG1Fc domain monomer. The invention also features pharmaceutical compositions and methods of using the same to treat diseases and conditions involving muscle weakness and atrophy, bone damage, low red blood cell levels (e.g., anemia or blood loss), fibrosis, and / or pulmonary hypertension.SELECTED DRAWING: Figure 2

Disclosed are methods of improving weight loss, reducing body weight, reducing body fat mass, reducing muscle loss, reducing muscle atrophy, reducing muscle weakness, increasing muscle mass, and / or increasing muscle strength in a patient being treated with a GLP-1 receptor agonist, by administering to the patient a compound of formula (I) or a pharmaceutically acceptable salt thereof. Combinations of a GLP-1 receptor agonist and a compound of formula (I) or a pharmaceutically acceptable salt thereof for use in improving weight loss, reducing body weight, reducing body fat mass, reducing muscle loss, reducing muscle atrophy, reducing muscle weakness, increasing muscle mass, and / or increasing muscle strength in a patient are also provided.

This document presents a novel composition and method for treating osteoarthritis using a cannabinoid-based nanoplatform administered via intra-articular injection. The composition includes phytocannabinoids such as CBG and CBC, along with hyaluronic acid, type II collagen, and calcium gluconate, embedded within a nanoplatform designed to enhance bioavailability and ensure controlled release in the synovial space. Tailored for osteoarthritis patients, the treatment alleviates joint pain, stiffness, reduced mobility, inflammation, sensations of friction, muscle weakness, and joint deformity. Cannabinoids act through multiple mechanisms, including interaction with CB1 and CB2 receptors, cytokine modulation, inhibition of NF-κB, and activation of the TRPV1 receptor, providing a potent anti-inflammatory effect. The formulation aims to halt cartilage degeneration, reduce pain, and slow osteoarthritis progression. The production process uses nanoemulsification techniques to create particles smaller than 200 nm, with pre-sterilization through membrane filtration, ensuring both efficacy and safety.

The application discloses a compound preparation beneficial to muscle nutrition, which is composed of yeast extract powder, yeast beta-1, 3-glucan and ginsenoside at a weight ratio of 8:1:1, and contains 200-800 mg of yeast extract powder in each unit of the preparation; wherein the essential amino acids beneficial to muscle nutrition include three branched-chain amino acids, specifically isoleucine, leucine and valine, and the ratio coefficient of the branched-chain amino acids is 1-1.2, and the ratio coefficient range is 0.94-1.14. The compound preparation can improve the symptoms caused by muscle attenuation syndrome, such as muscle weakness, osteoporosis and myocardial function degradation, has the advantages of easy absorption, high safety, synergistic effect and the like, and is suitable for the old, the weak and the people with decreased sports ability.

Disclosed are methods of improving weight loss, reducing body weight, reducing body fat mass, reducing muscle loss, increasing muscle mass, and / or increasing muscle strength in a subject being treated with a GLP-1 receptor agonist, by administering to the subject a compound of formula (I) or a pharmaceutically acceptable salt thereof. Combinations of a GLP-1 receptor agonist and a compound of formula (I) or a pharmaceutically acceptable salt thereof for use in improving weight loss, reducing body weight, reducing body fat mass, reducing muscle loss, reducing muscle atrophy, reducing muscle weakness, increasing muscle mass, and / or increasing muscle strength in a subject are also provided.

Disclosed herein are products, methods, and uses for treating, ameliorating, delaying the progression of, and / or preventing a disease or disorder associated with expression of an aberrant lamin A (LMNA) gene or progerin gene. Such disease or disorder includes, but is not limited to, a laminopathy, progeroid syndrome, progeria, or aging disorder resulting from the aberrant expression of LMNA or progerin. In some instances, the progeria is Hutchinson-Gilford progeria syndrome (HGPS). In some instances, the disease or disorder associated with the expression of progerin is premature aging or natural aging including, but not limited to, atherosclerosis, alopecia, osteoporosis, cardiovascular disease, skin abnormalities, fat storage, stroke, myocardial infarction, stroke, heart failure, muscle wasting, muscle weakness, myotonia, skeletal muscle problems, abnormalities of the retina, hip weakness, abdominal muscle weakness, joint and spinal abnormalities, lower leg weakness, shoulder weakness, hearing loss, and / or tissue inflammation. More particularly, disclosed herein are RNA interference-based products, methods, and uses for inhibiting or downregulating the expression of progerin. Even more particularly, the disclosure provides guide RNA and a CRISPR endonuclease for inhibiting or downregulating the expression of progerin and methods of using said guide RNA and a CRISPR endonuclease to correct a mutation in the LMNA gene and inhibit or downregulate progerin expression in cells and / or in cells of a subject having a condition resulting from the expression of progerin including, but not limited to, HGPS or progeria, an HGPS-like condition affecting LMNA mutations that affect exon 11 splicing, or a condition resulting from the expression of progerin.

This invention discloses an early assisted standing posture system and method to promote lung expansion after lung transplantation, belonging to the field of medical rehabilitation technology. The system includes a data acquisition module, a muscle strength assessment and compensation decision module, a power-assisted execution module, an embracing psychological support module, an emotion monitoring and response module, and a process control module. It uses multi-sensor fusion technology to identify the specific locations of muscle weakness in patients in real time, uses intelligent decision-making algorithms to calculate the required compensation assistance, and provides dynamic compensation through precise power-assisted devices. At the same time, it integrates multi-dimensional psychological support such as a forward embracing structure, voice guidance, and bionic body temperature and tactile feedback to achieve a synergistic effect of physiological function compensation and psychological and emotional support, providing safe, efficient, and humane early standing rehabilitation training for patients after lung surgery.

The invention discloses a stir-frying method of ginseng and a preparation method of ginseng nourishing paste containing the stir-fried ginseng. The ginseng stir-frying method comprises the following steps: performing biological infiltration on ginseng by using active dry yeast under an acidic condition, and then performing high-pressure steaming with specific parameters and low-temperature long-time drying. According to the processing method, the ginsenoside Rg component easily causing'internal heat 'can be remarkably converted and reduced, other rare saponins are enriched, and the'slow tonifying' characteristic of ginseng is achieved. On the basis, the invention also provides a preparation method of the ginseng nourishing paste, and the preparation method comprises the following steps: scientifically matching the stir-fried radix ginseng, radix astragali, rhizoma polygonati, folium cortex eucommiae, rhizoma dioscoreae and other medicinal and edible raw materials, extracting with ethanol, concentrating, and co-refining with erythritol and other auxiliary materials to obtain the paste. According to the nourishing paste, the tonifying effect of the ginseng core is reserved, meanwhile, the taste and bioavailability are greatly improved, and the nourishing paste is suitable for being taken by middle-aged and elderly people especially people with muscular tension weakness caused by degenerative amyotrophy for a long time so as to achieve the health-care effects of tonifying qi, relieving desertion, relaxing the channels, dredging collaterals, activating the pulse and preventing the degenerative amyotrophy and the muscular tension weakness.

This invention provides a mixture of three strains of Lactobacillus fermentum and Lactobacillus platarum, as well as its uses. [Solution] A composition comprising a mixture of Lactobacillus fermentum GB102, GB103 strains and Lactobacillus plantarum GB104 strain, and their lysates, cultures, or extracts of cultures as active ingredients, can be usefully used for the prevention or treatment of muscle-related diseases or obesity, such as by alleviating age-related muscle weakness symptoms or reducing age-related changes in the intestinal microbial environment.

Disclosed are a system for detecting a cardiac function in a walk test, and an electronic device thereof, comprising: acquiring first inertial measurement information, wherein the first inertial measurement information represents inertial measurement information of a subject's body; extracting to obtain, according to the first inertial measurement information, seismocardiogram information; extracting to obtain, according to the first inertial measurement information, walking information; and analyzing to obtain, according to the seismocardiogram information and the walking information, an identification result regarding cardiac function. Without being limited by walking sites, walking time, and medical staff, the use of a walk test outside the hospital is greatly facilitated, the specificity of cardiac function assessment is achieved, and the interference to data processing caused by other diseases, such as muscle weakness and pulmonary dysfunction of a subject during walking, is eliminated.

There are provided polypeptides that include an Activin receptor type IIB (ActRIIB) ectodomain (ECD) variant. In some embodiments, a polypeptide of the disclosure includes an ActRIIB-ECD variant fused to an Fc domain moiety. The disclosure also provides pharmaceutical compositions and methods of using the polypeptides to treat diseases and conditions associated with TGFβ superfamily ligand signaling, such as metabolic disorders, diabetes, obesity, cardiometabolic disease, pulmonary hypertension, fibrosis, muscle weakness and atrophy, bone damage, and / or low red blood cell levels (such as anemia).

The invention provides a system suitable for detecting cardiac functions in a walking test and electronic equipment thereof, and the method comprises the following steps: obtaining first inertial measurement information which represents inertial measurement information of a subject body; according to the first inertial measurement information, extracting heart earthquake information; according to the first inertial measurement information, extracting walking information; and according to the cardiac shock information and the walking information, analyzing to obtain an identification result about the cardiac function. The method is not limited by walking sites, walking time and medical staff, greatly facilitates use of walking tests outside hospitals, achieves specificity of cardiac function evaluation, eliminates interference of muscle weakness, pulmonary dysfunction and other diseases of subjects in the walking process on data processing, and improves the accuracy of cardiac function evaluation. The method is an innovative development of traditional walking tests which are used for many years all over the world.

To provide polypeptides that include an extracellular ActRII chimera.SOLUTION: Provided is a polypeptide of the present invention including an extracellular ActRII chimera fused to an Fc domain monomer or moiety. The invention also features pharmaceutical compositions and methods of using the polypeptides to treat diseases and conditions involving weakness and atrophy of muscles, bone damage, low red blood cell levels (e.g., anemia or blood loss), low platelet levels (e.g., thrombocytopenia), low neutrophil levels (e.g., neutropenia), fibrosis, metabolic disorders, and / or pulmonary hypertension.SELECTED DRAWING: None

The application discloses a kind of intelligent physiological training parameter optimization adjustment system and method, belong to physiological training control technical field, including: first, obtain user multi-source baseline physiological signal sequence and training stage parameter, identify skeletal muscle fiber type and construct multi-training target decoupling control model, generate the control configuration data containing muscle fiber targeted execution action parameter interval, dynamic safety threshold curve, body pressure-muscle collaborative constraint rule;Subsequently, start parameter iteration optimization, collect physiological feedback signal, calculate four core indexes, and output muscle basic function diagnosis result after comprehensive difference meets standard;Finally, output rehabilitation action according to preset rhythm, continuously collect signal and identify abnormality such as spasm, muscle weakness, trigger intensity rollback or enhancement mechanism;The application realizes the precision, intelligent adjustment of pelvic floor rehabilitation parameter, improves rehabilitation safety and effectiveness, adapts to the individualized rehabilitation needs of different users.

The invention relates to a space capsule nanometer bath therapy instrument which comprises a base, and a bath cabin is arranged at the upper end of the base. A closed bath cavity is formed in the bath cabin, a human body lies on the bath cabin, and the part below the head of the human body is located in the bath cavity; a nano particle bath assisting device is arranged in the base, and water is converted into vaporific nano water particles by the nano particle bath assisting device; a spray pipe located in the bath cavity is arranged in the bath cabin, an outlet of the spray pipe faces the human body, and an inlet is connected with an outlet of the nanoparticle bath assisting device; the inner cavity of the base, the nano particle bath assisting device, the spray pipe and the bath cavity form an annular channel; and the nano-particle bath assisting device comprises a centrifugal fan, so that nano-water particles circularly flow in the channel. The lying type design is adopted, the potential safety hazards such as falling and slipping caused by muscle weakness, poor balance capacity or limited joint movement are effectively avoided, the lying type bathing device is particularly suitable for disabled and semi-disabled people and postoperative rehabilitation patients, and the safety risk caused by a traditional showering mode is greatly reduced.

The present disclosure provides polypeptides comprising an activin type IIB receptor (ActRIIB) extracellular domain (ECD) variant. In some embodiments, the polypeptides of the present disclosure include an ActRIIB-ECD variant fused to an Fc domain moiety. The disclosure also provides pharmaceutical compositions and methods of using the polypeptides in the treatment of diseases and conditions associated with TGF [beta] superfamily ligand signaling, such as metabolic disorders, diabetes, obesity, cardiac metabolic disease, pulmonary hypertension, fibrosis, muscle weakness and atrophy, bone injury, and / or low red blood cell levels, such as anemia.

Disclosed herein are products, methods, and uses for treating, ameliorating, delaying the progression of, and / or preventing a disease or disorder associated with expression of an aberrant lamin A (LMNA) gene or progerin gene. Such disease or disorder includes, but is not limited to, a laminopathy, progeroid syndrome, progeria, or aging disorder resulting from the aberrant expression of LMNA or progerin. In some instances, the progeria is Hutchinson-Gilford progeria syndrome (HGPS). In some instances, the disease or disorder associated with the expression of progerin is premature aging or natural aging including, but not limited to, atherosclerosis, alopecia, osteoporosis, cardiovascular disease, skin abnormalities, fat storage, stroke, myocardial infarction, stroke, heart failure, muscle wasting, muscle weakness, myotonia, skeletal muscle problems, abnormalities of the retina, hip weakness, abdominal muscle weakness, joint and spinal abnormalities, lower leg weakness, shoulder weakness, hearing loss, and / or tissue inflammation. More particularly, disclosed herein are RNA interference-based products, methods, and uses for inhibiting or downregulating the expression of progerin. Even more particularly, the disclosure provides guide RNA and a CRISPR endonuclease for inhibiting or downregulating the expression of progerin and methods of using said guide RNA and a CRISPR endonuclease to correct a mutation in the LMNA gene and inhibit or downregulate progerin expression in cells and / or in cells of a subject having a condition resulting from the expression of progerin including, but not limited to, HGPS or progeria, an HGPS-like condition affecting LMNA mutations that affect exon 11 splicing, or a condition resulting from the expression of progerin.

The present invention relates to a composition for preventing, improving, or treating diseases associated with muscle weakness, comprising a celery seed extract. The celery seed extract according to the present invention is a natural product and can increase muscle mass and strength with few or no side effects. Therefore, it is expected that the celery seed extract according to the present invention can be useful for preventing, improving, or treating diseases associated with muscle weakness, metabolic diseases, liver diseases, etc., since it can increase muscle mass and strength with few or no side effects by using a natural product and can not only prevent muscle weakness, but also inhibit increases in body weight and body fat, and reduce blood lipid concentrations and liver toxicity indicators (GOT and GPT).

The utility model belongs to the field of medical rehabilitation instruments, and particularly relates to a multifunctional rehabilitation chair for neurological rehabilitation, which comprises a rehabilitation chair main body, vertical rods are assembled on the rehabilitation chair main body, connecting blocks are assembled on the vertical rods, fixed blocks are assembled on the connecting blocks, rotating rods are assembled on the fixed blocks, adjusting blocks are assembled on the rotating rods, and supporting blocks are assembled on the adjusting blocks. The supporting block is provided with a traction groove, the traction groove is provided with a guide rod, the traction groove is provided with a transmission lead screw, the transmission lead screw is provided with a knob, the transmission lead screw is provided with a traction block, the traction block is assembled with the guide rod, the traction block is provided with an assembly block, the assembly block is provided with an extension block, the extension block is provided with a bearing pedal, and the bearing pedal is provided with a containing groove. According to the multifunctional rehabilitation chair for neurological rehabilitation, through cooperation of the bearing pedal and the rotating rod, the problems that after a patient does not use leg muscles for a long time, the patient is likely to have symptoms such as myasthenia, muscle atrophy occurs, and the body health and disease recovery of the patient are seriously affected are solved.

An antisense oligonucleotide of 15-30 bases or a salt or a solvate thereof, wherein the antisense oligonucleotide has a nucleotide sequence complementary to a target site in exon 1 of the myostatin gene and is capable of inhibiting the production of the mRNA of the myostatin gene. A pharmaceutical drug, a food, a feed, an agent for promoting myocyte proliferation and / or hypertrophy, an agent for increasing muscle mass and / or inhibiting muscle weakness, an agent for inhibiting production of the mRNA of the myostatin gene, and an inhibitor of the function of myostatin, each of which comprises the above antisense oligonucleotide or a salt or a solvate thereof.

Short expansion mutations in PABPN1 cause adult-onset, autosomal dominant oculopharyngeal muscular dystrophy (OPMD). The molecular hallmark of OPMD is the presence of insoluble nuclear aggregates of the expanded (exp)PABPN1. The aggregation of PABPN1 results in reduced levels of functional PABPN1. In OPMD, PABPN1 levels are under a critical threshold which leads to muscle weakness. Interestingly, reduced levels of PABPN1 are also found in ageing muscles, where these reduced levels lead to muscle atrophy and has also been found to be associated with other adult-onset pathologies affecting tissues other than skeletal muscles, such as cancers, including bladder cancer, and heart diseases.